One day after Celgene's stock hit a four-year low, the big biotech inked a drug discovery deal with Germany's Evotec. Evotec will use its preclinical discovery and development platform — including its phenotypic screening platform and …
Investors didn’t like the sound of it. Celgene’s stock plunged 5% after the story …
Biotech heavyweight Celgene has a 45x P/E, but the stock is cheap. Utilizing operating earnings lowers the multiple, but when evaluating biotech companies, I generally don't favor determining fair value by using operating earnings. …
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that …
But should investors stay clear of Celgene stock after the big blunder, or is now a great time to buy? Celgene stated that "the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a …
SmarTrend identified a Downtrend for Celgene Corp (NASDAQ:CELG) on October 13th, 2017 at $137.01. In approximately 6 months, Celgene Corp has returned 33.57% as of today's recent price of $91.01. In the past 52 weeks, Celgene Corp …
As a result of these false statements and/or omissions, the price of Celgene stock was artificially inflated during the …